Researchers in New Mexico and Croatia have tested a non-invasive brain scanning technique known as magnetoencephalography, or MEG, as an early biomarker of Alzheimer's disease.
Axovant Sciences today announced that the Phase 3 MINDSET trial of its Alzheimer’s drug intepirdine has failed to bring meaningful improvements in cognition or daily functioning.
Researchers have found that despite having complex needs, most of the healthcare received by people in the later stages of dementia is provided by GPs or emergency services, with little support from specialist healthcare professionals.